Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for five companies, including Guizhi Yan Pharmaceutical, which is undergoing a transition from private to public listing [1] - Guizhi Yan Pharmaceutical is required to clarify the compliance of its equity control structure and provide detailed information regarding share price changes in the 12 months prior to its application [1][2] - The company is also asked to explain the reasons why its beneficial owner, Shi Mingfeng, has not been recognized as a co-actual controller [1] Group 2 - Maius Pharmaceutical Technology, established in 2015 and headquartered in Shanghai, focuses on the research and development of innovative formulations and targeted small molecule drugs, particularly in oncology, immune system diseases, and anti-infection [3] - The company has developed a comprehensive R&D platform that integrates chemical drug screening and delivery, significantly enhancing drug development efficiency and precision [3] - Maius is set to achieve its strategic goal of going public on NASDAQ through a merger with DT Cloud Acquisition Corporation, with an overall valuation of $250 million [2]